Avexa Limited is an Australia-based biotechnology company with a focus on research and development of anti-infectives. The Company is developing drugs for the treatment of infectious diseases. During the fiscal year ended June 30, 2008 (fiscal 2008), the Company was engaged in anti-infective pharmaceutical programs and projects. During fiscal 2008, Avexa initiated a Phase III development program for its lead product, apricitabine (ATC), and received positive data from the 48-week Phase IIb study for ATC. In fiscal 2008, the human immunodeficiency virus (HIV) integrase and antibacterial projects also progressed towards pre-clinical studies. In its Integrase program, the Company has developed a number of small molecules that inhibit HIV infection of cells. Avexa Limited has entered into a collaboration with TargetDrug of Shanghai to develop small molecule inhibitors of hepatitis C virus (HCV).
(Source: ARS)
